Lexaria Introduces TurboCBD Brand of High Absorption Full Spectrum Hemp Oil Capsules Kelowna, BC /

Lexaria Introduces TurboCBD Brand of High Absorption Full

Spectrum Hemp Oil Capsules

Kelowna, BC / March 22, 2017 / Lexaria Bioscience Corp.

(OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces the introduction

of the TurboCBD brand of technologically enhanced, high absorption full

spectrum hemp oil capsules. Lexaria s TurboCBD capsules are specially

formulated with the finest American Ginseng and Ginkgo Biloba for support of

enhanced focus and memory, and reduced stress and fatigue.

TurboCBD capsules utilize Lexaria s patented absorption

technology and are triple tested for purity. They are made without the use of

organic solvents and leave no hemp oil aftertaste. They are vegan, gluten-free,

sugar-free, nut-free and made in the USA. They will soon be offered for sale

through California medical cannabis dispensaries and other select locations as

the perfect complement to any cannabis regimen.

Lexaria s TurboCBD capsules are designed to work with the

physiology of the human gastrointestinal system where minute quantities of long

chain fatty acids like sunflower oil, combined in each serving of TurboCBD

capsules, are thoroughly and quickly absorbed into the circulatory system for

maximum effectiveness. In vitro and human focus study testing has shown

increases in CBD absorption using Lexaria s technology by as much as 5-10 times

more than conventional preparations. Those studies also demonstrated rapid onset

of action in as little as 15 minutes.

Lexaria intends to showcase its TurboCBD capsules at the

upcoming 2017 World Medical Marijuana Business Conference & Expo in

Pittsburgh on April 21 and 22, which is expected to attract over 8,000 cannabis

professionals including 1,200 physicians interested in the sector.

further researching other capsule formulations utilizing its patented

absorptiontechnology, each of which would be uniquely formulated to address

specific market demands. Testing with Lexaria s technology has shown equally

good improvements in enhancing absorption and rapidity of action when working with THC as

shown for CBD, and Lexaria continues to develop and seek opportunities to lever

its technology for THC product applications through licensees in the USA, Canada

and internationally.

Lexaria Bioscience Corp. is a food

biosciences company with a proprietary technology for improved delivery of

bioactive compounds. The Company s lipophilic enhancement technology has been

shown to enhance the bioavailability of orally ingested cannabinoids, while also

improving taste. This technology promotes healthy ingestion methods, lower

overall dosing and higher effectiveness in active molecule delivery. The

Company s technology is patent-protected for cannabidiol (CBD) and all other

non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol

(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs

(NSAIDs), nicotine and other molecules.

FOR FURTHER INFORMATION PLEASE CONTACT:

FORWARD-LOOKING STATEMENTS

This release includes

forward-looking statements. Statements which are not historical facts are

forward-looking statements. The Company makes forward-looking public statements

concerning its expected future financial position, results of operations, cash

flows, financing plans, business strategy, products and services, competitive

positions, growth opportunities, plans and objectives of management for future

operations, including statements that include words such as "anticipate," "if,"

"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"

"will," and other similar expressions are forward-looking statements, including

but not limited to: that any additional stock warrants or stock options will be

exercised. Such forward-looking statements are estimates reflecting the

Company's best judgment based upon current information and involve a number of

risks and uncertainties, and there can be no assurance that other factors will

not affect the accuracy of such forward-looking statements. Access to capital,

or lack thereof, is a major risk and there is no assurance that the Company will

be able to raise required working capital. Factors which could cause actual

results to differ materially from those estimated by the Company include, but

are not limited to, government regulation, managing and maintaining growth, the

effect of adverse publicity, litigation, competition, the patent application and

approval process and other factors which may be identified from time to time in

the Company's public announcements and filings. There is no assurance that

existing capital is sufficient for the Company's needs or that it will be able

to raise additional capital. There is no assurance that Lexaria will

successfully complete any other contemplated or existing technology license

agreements. There is no assurance that any planned corporate activity, business

venture, or initiative will be pursued, or if pursued, will be successful. There

is no assurance that any of Lexaria s postulated uses, benefits, or advantages

for the patented and patent-pending technology will in fact be realized in any

manner or in any part. No statement herein has been evaluated by the Food and

Drug Administration (FDA). Lexaria Energy Foods and ViPovaTM products

are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility

for the adequacy or accuracy of this release.